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Background: Nocturnal oxyhaemoglobin desaturation is common in cystic fibrosis (CF) but the effect on quality of life (QoL) remains unknown.
Methods: Sixty stable CF outpatients with mean age 31±8 years (mean±1SD), BMI 20.8±3.2 kg/m2 and FEV1 42±13% predicted had arterial
blood gas sampling, lung function testing, overnight pulse oximetry and completed the CF QoL questionnaire, Epworth Sleepiness Scale and
Medical Research Council dyspnoea scale.
Results: 11 (18%) of the CF patients were ‘desaturators,’ (SpO2b90% for ≥30% recording time on overnight oximetry). Desaturators had greater
difficulty performing their treatments (39±22 vs 61±26, pb0.01) and more exertional dyspnoea (3.2±0.8 vs 2.0±0.9, pb0.001) than non-
desaturators after controlling for the effects of FEV1, awake PaO2 and PaCO2 (adjusted p-values b0.01 and 0.04 respectively).
Conclusions: Nocturnal oxyhaemoglobin desaturation is associated with impaired QoL, independent of the effects of lung function and awake gas
exchange, in stable CF outpatients with moderate to severe lung disease.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Nocturnal oxygen desaturation; Quality of life1. Background
Cystic fibrosis (CF) is characterized by a progressive decline
in lung function resulting in impaired quality of life (QoL) [1].
Nocturnal oxyhaemoglobin desaturation accompanies the
decline in lung function [2]. It remains unknown whether
nocturnal oxyhaemoglobin desaturation is an independent
predictor of impaired QoL in CF.
Nocturnal oxyhaemoglobin desaturation is common in CF
subjects with severe lung disease, awake hypoxia and hypercap-
nia [3,4]. It appears to result from alveolar hypoventilation,
impaired lung mechanics and ventilation–perfusion mismatching
[5,6], which all worsen as lung function declines. Nocturnal☆ ClinicalTrials.gov Identifier: NCT00157183.
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hypertension [7], reduced sleep efficiency [8] and neurocognitive
dysfunction during acute exacerbations [9]. Whether these latter
effects translate into reduced QoL, independent of lung function
and awake gas exchange, remains unknown.
Overnight oximetry is convenient, non-invasive and can
provide an accurate, reproducible measure of overnight oxygen-
ation in CF patients [10,11]. It has been used to detect nocturnal
oxyhaemoglobin desaturation in CF patients at home [4].
Definitions vary across countries and in the published literature,
but current CF guidelines recommend treatment if the oxyhae-
moglobin saturation measured by pulse oximetry (SpO2) is b88–
90% for ≥10% of the night [12]. In Australia, nocturnal oxygen
therapy is government-funded for patients with an SpO2≤88%
for ≥30% of the night [13]. A validated CF-specific QoL
instrument is now available [14].
The study hypothesis was that nocturnal oxyhaemoglobin
desaturation would impact negatively on QoL in CF, independent
of the effects of lung function and awake gas exchange. The aimd by Elsevier B.V. All rights reserved.
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disease to determine (i) the prevalence of nocturnal oxyhaemo-
globin desaturation (ii) whether nocturnal oxyhaemoglobin
desaturation impacted negatively on QoL (iii) if these effects
occurred independent of lung function (FEV1) and awake gas
exchange (PaO2 and PaCO2) and (iv) whether a threshold existed
for nocturnal oxyhaemoglobin desaturation that was associated
with a reduction in QoL.
2. Methods and materials
2.1. CF patients
Written informed consent was obtained after study approval
by The Alfred Hospital Institutional Ethics Committee.
Consecutive outpatients were recruited from The Alfred
Hospital Adult CF Service which has a statewide population
base of 220 patients. Inclusion criteria were age ≥18 years,
confirmed diagnosis of CF by standard criteria [12],
FEV1≤70% predicted and clinical stability (no hospitalization
or new antibiotics in two weeks prior). Exclusion criteria were
previous domiciliary oxygen therapy or non-invasive ventila-
tion, current sedative use, cardiac or neurological disease or
symptoms of obstructive sleep apnoea.
2.2. Physiological data
Home overnight oximetry (Oxypleth, Novametrix, Connecticut,
USA) was performed with a two second averaging time and
sampling frequency of 0.125 Hz. Download software (Download
2001, StowoodScientific, Oxford,UK) analysed the recording time
to calculate: % recording time with SpO2b90%, mean SpO2,
minimum SpO2 and mean heart rate. Patients were classified as
‘non-desaturators’ or ‘desaturators’ at two different thresholds:
SpO2b90% for ≥10% of the recording time (10% threshold) or
SpO2b90% for ≥30% of the recording time (30% threshold),
based on current expert guidelines [12,13]. Awake supine arterial
blood gases (ABG)were takenwith a 25 gauge needle and analysed
(model 865, Bayer HealthCare, NY, USA). Spirometry and lung
volumes were performed (Profiler and Elite Series, Medgraphics,
MN,USA) toAmerican Thoracic Society criteria [15]. Height (cm)
and weight (kg) were used to calculate body mass index (BMI).
2.3. Quality of life
Validated QoL measures assessed CF-specific domains (CF
QoL Questionnaire) [14], subjective daytime sleepiness
(Epworth Sleepiness Scale) [16], subjective sleep quality
(Pittsburgh Sleep Quality Index) [17] and dyspnoea (Medical
Research Council Dyspnoea Scale) [18]. Patients were asked if
they had regularly worked or studied over the last month.
The CF QoL Questionnaire (CFQoL) is a reliable and valid
measure [14]. It assesses nine functional domains: physical
functioning, social functioning, treatment issues, chest symp-
toms, emotional responses, concerns for the future, interper-
sonal relationships, body image and career concerns, producing
a score from 0 (worst) to 100 (best) in each. A 10 point change isconsidered clinically important [1]. The Epworth Sleepiness
Scale (ESS) is a validated sleep questionnaire with a score N10
indicating subjective daytime sleepiness [16]. The Pittsburgh
Sleep Quality Index (PSQI) assesses sleep quality and
disturbance [17]. Seven components are combined to produce
a global score of 0–21. A score N5 is a sensitive and specific
measure of poor sleep quality. The Medical Research Council
Dyspnoea scale (MRC) is a validated measure of dyspnoea in
COPD [19]. It grades the effect of breathlessness on daily
activities to produce five categories of perceived respiratory
disability from zero (none) to four (very severe) [18]. It
correlates with exercise capacity in patients with CF [20].
2.4. Statistical analysis
Data are presented as means±1SD or frequencies(%). Non-
desaturators were compared to desaturators at the 10% and 30%
thresholds. The unpaired t-test and Wilcoxon test (continuous
variables) or Chi-square test and Fisher's Exact test (categorical
variables) were used. Where a significant difference in QoL
(dependent variable) was identified between non-desaturators
and desaturators (independent variable) a one-way between-
groups analysis of co-variance was performed to control for the
effects of FEV1, awake PaO2 and PaCO2 (covariates).
Univariate analysis was then performed using simple linear
correlations to explore the relationships between mean
nocturnal SpO2, minimum nocturnal SpO2 and QoL measures.
Where a significant relationship was identified, multiple
regression was performed using the QoL variable as the
dependent variable and mean or minimum nocturnal SpO2,
FEV1, and awake PaO2 as the independent variables.
Alpha was set at 0.05 for all tests. Assuming a standard
deviation of 15 points for the physical function domain of the
CFQoL [21] a sample size of 18 patients was needed in each
group (non-desaturator and desaturator) to detect a 10 point
difference (clinically important difference) with a power of 0.8
and a two-sided α of 0.05.
3. Results
3.1. Patient characteristics
Sixty CF patients were studied. The patient demographics,
FEV1, arterial blood gases and overnight oximetry results are
given in Table 1. Sixteen (27%) patients were classified as
desaturators using the 10% threshold (SpO2b90% for≥10% of
the recording time) whilst eleven (18%) patients were classified
as desaturators using the 30% threshold (SpO2b90% for≥30%
of the recording time) (Table 1).
3.2. Comparison of non-desaturators and desaturators using
10% threshold
The two groups had similar BMI and pH. Desaturators had
decreased FEV1, PaO2, awake SaO2 and increased PaCO2
compared to non-desaturators (Table 2). Examining QoL,
desaturators were not significantly different on any domain of
Table 1
Demographics and clinical parameters for CF patients.
Characteristics CF patients
Number 60
Age, yr 31±8
Sex 36 M 24 F
BMI, kg/m2 20.8±3.2
FEV1, % 42±13
pH 7.41±0.03
PaCO2, mm Hg 42±5
PaO2, mm Hg 75±12
SaO2, % 96±3
Overnight oximetry a
Mean SpO2, % 93±4
Minimum SpO2, % 84±7
Time SpO2b90%, % 14±27
Desaturators 10% threshold, n (%) 16 (27)
Desaturators 30% threshold, n (%) 11 (18)
Mean heart rate, beats/min 74±13
Values are mean±SD. BMI = Body mass index, Desaturators 10% threshold =
Subjects spending≥10% of recording time with SpO2b90%, Desaturators 30%
threshold = Subjects spending≥30% of recording time with SpO2b90%.
a Values are calculated for recording time overnight.
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compared to non-desaturators. Desaturators did have greater
exertional dyspnoea on the MRC (Table 2). However, after
adjusting for the effects of FEV1, awake PaO2 and PaCO2 these
differences did not remain significant (Table 2).Table 2
Comparison cystic fibrosis non-desaturators vs destaurators using 10% threshold.
Characteristics Non-desat Desat
Number, (%) 44 (73) 16 (27)
Age, yr 30±7 31±9
Sex 25 M 19 F 11 M/5 F
BMI, kg/m2 21.2±3 19.8±3
FEV1, % 45±11 33±13
pH 7.41±0.03 7.41±0.03
PaCO2, mm Hg 40±3 46±6
PaO2, mm Hg 79±9 65±14
SaO2, % 97±1 92±4
Quality of Life
CFQoL (0=worst,100=best)
Physical function 77±19 67±20
Social function 73±25 70±26
Treatment issues 59±26 51±27
Chest symptoms 63±27 56±23
Emotional response 73±25 77±14
Concerns for future 40±28 43±30
Relationships 55±26 53±23
Body image 57±30 55±19
Career concerns 53±30 53±26
ESS (0=best, 24=worst) 5.3±3.1 6.5±3.7
PSQI (0=best, 21=worst) 7.8±3.9 6.8±2.7
MRC (0=best, 4=worst) 2.0±0.9 2.8±1.0
Work or study, % 82 63
Values are mean±SD. Non-desat = SpO2b90% for b10% recording time, Desat=S
Quality of Life questionnaire, ESS = Epworth sleepiness scale, PSQI = Global scor
Scale.
a Adjusted for differences in FEV1, awake PaO2 and PaCO2.3.3. Comparison of non-desaturators and desaturators using
30% threshold
Desaturators had decreased FEV1, awake PaO2, SaO2 and
increased PaCO2 compared to non-desaturators (Table 3).
Desaturators had reduced physical functioning, increased treat-
ment issues and more chest symptoms on the CFQoL.
Desaturators had more subjective daytime sleepiness on the
ESS and greater exertional dyspnoea on theMRC (Table 3). After
adjusting for the effects of FEV1, awake PaO2 and PaCO2, the
treatment issues domain on the CFQoL (Fig. 1) and the MRC
remained significantly worse in desaturators, with a trend towards
worsening for the physical functioning domain of the CFQoL
(Table 3). Nocturnal oxyhaemoglobin desaturation independently
explained 15%, 8% and 6% of the variance in the treatment issues
domain, MRC and physical functioning domain respectively.
3.4. Correlations between nocturnal oxygen saturation and
QoL
Mean nocturnal SpO2 correlated significantly with the
physical functioning domain of the CFQOL, ESS and MRC.
However, none of these relationships remained significant after
adjusting for the effects of FEV1 and awake gas exchange
(PaCO2, PaO2), although there was a trend towards an
independent effect of mean nocturnal SpO2 on MRC
(Table 4). Minimum nocturnal SpO2 correlated significantly95% CI for difference p Adjust p a
−5 to 4 0.8
−0.4 to 3 0.1
6 to 19 b0.001
−0.02 to 0.02 0.9
−8 to −3 b0.001
8 to 19 b0.001
3 to 6 b0.001
−2 to 21 0.1
−12 to 18 0.7
−7 to 24 0.3
−8 to 23 0.3
−17 to 10 0.6
−20 to 14 0.7
−12 to 18 0.7
−15 to 17 0.9
−17 to 17 1.0
−3 to 0.7 0.2
−1.6 to 3.7 0.4
−1.3 to −0.2 b0.01 0.4
0.2
pO2b90% for ≥10% recording time, BMI = Body mass index, CF QoL = CF
e Pittsburgh Sleep Quality Index, MRC = Medical Research Council Dyspnoea
Table 3
Comparison cystic fibrosis non-desaturators and desaturators using 30% threshold.
Characteristics Non-desat Desat 95% CI for difference p Adjust p a
Number, (%) 49 (82) 11 (18)
Age, yr 30±7 31±10 −6 to 4 0.7
Sex 28 M 21 F 8 M 3 F
BMI, kg/m2 21.1±3.1 19.4±3.3 −0.4 to 4 0.1
FEV1, % 45±11 26±8 12 to 26 b0.001
pH 7.41±0.03 7.41±0.03 −0.02 to 0.02 1.0
PaCO2, mm Hg 41±3 47±6 −9 to −4 b0.001
PaO2, mm Hg 77±9 64±16 7 to 21 b0.001
SaO2, % 97±2 92±4 4 to 7 b0.001
Quality of Life
CFQoL (0=worst,100=best)
Physical function 79±19 58±15 9 to 33 b0.01 0.07
Social function 75±25 61±26 −3 to 31 0.1
Treatment issues 61±26 39±22 5 to 39 b0.01 b0.01
Chest symptoms 65±26 46±19 2 to 36 0.03 0.2
Emotional response 75±24 71±13 −11 to 20 0.6
Concerns for future 42±28 37±9 −14 to 24 0.6
Relationships 57±26 47±20 −7 to 27 0.2
Body image 58±29 49±18 −9 to 28 0.3
Career concerns 53±30 52±25 −19 to 21 0.9
ESS (0=best, 24=worst) 5.1±3.0 7.6±3.8 −4.6 to −0.4 0.02 0.2
PSQI (0=best, 21=worst) 7.7±3.7 7±3 −2.5 to 3.9 0.7
MRC (0=best, 4=worst) 2.0±0.9 3.2±0.8 −1.8 to −0.6 b0.001 0.04
Work or study, % 55 55 0.1
Values are mean±SD. Non-desat = SpO2b90% for b30% recording time, Desat = SpO2b90% for ≥30% recording time, BMI = Body mass index, CF QoL = CF
Quality of Life questionnaire, ESS = Epworth sleepiness scale, PSQI = Global score Pittsburgh Sleep Quality Index, MRC = Medical Research Council Dyspnoea
Scale.
a Adjusted for differences in FEV1, awake PaO2 and PaCO2.
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However, none of these relationships remained significant after
adjusting for the effects of FEV1 and awake gas exchange
(PaCO2, PaO2) (Table 4).
4. Discussion
The main finding in this study was that stable CF patients with
moderate to severe lung disease and nocturnal oxyhaemoglobin
desaturation had reduced QoL compared to ‘non-desaturators’.0
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Fig. 1. Cystic Fibrosis Quality of Life Questionnaire means domain scores according
Desat 30% (adjusted for FEV1, awake PaO2 and PaCO2). Non-desat = Mean score for
patients with SpO2b90% for ≥10% recording time. Desat 30% = Mean score for pUsing the ‘30% threshold’ (SpO2b90% for ≥30% of the
recording time on overnight oximetry) 18% of CF patients were
classified as having nocturnal oxyhaemoglobin desaturation.
These CF ‘desaturators’ had more difficulty performing treat-
ments, greater exertional dyspnoea and trended towards a
reduction in physical functioning compared to CF ‘non-
desaturators’. These positive findings remained significant after
correcting for the effects of FEV1, awake PaO2 and PaCO2.
However, it should be acknowledged that although significant,
the effect was small, with nocturnal oxyhaemoglobin desaturationNon-desat
Desat 10%
Desat 30%
to nocturnal oxyhaemoglobin saturation. * adjusted p-value b0.01 Non-desat vs
patients with SpO2b90% for b10% recording time. Desat 10% =Mean score for
atients with SpO2b90% for ≥30% recording time.
Table 4
Correlation between nocturnal oxygen saturation and quality of life in CF patients.
Mean nocturnal SpO2 (n=60) Minimum nocturnal SpO2 (n=60)
Quality of life R p-value Adjust p-value a R p-value Adjust p-value a
CFQoL (0=worst, 100=best)
Physical function 0.34 0.01 0.8 0.24 0.08 0.8
Social function 0.16 0.2 0.21 0.1
Treatment issues 0.11 0.4 0.15 0.3
Chest symptoms 0.25 0.06 0.7 0.26 0.05 0.4
Emotional response 0.01 1 0.03 0.8
Concerns for future −0.01 0.9 0.12 0.4
Relationships 0.21 0.12 0.17 0.2
Body image 0.03 0.8 0.11 0.4
Career concerns −0.03 0.8 −0.01 1
ESS (0=best, 24=worst) −0.26 0.04 0.6 −0.19 0.2 0.9
PSQI (0=best, 21=worst) 0.09 0.6 −0.01 0.9
MRC (0=best, 4=worst) −0.52 b0.001 0.08 −0.44 b0.01 0.2
Work or study, % 0.23 0.08 0.9 0.2 0.1 0.6
BMI = Body mass index, CF QoL = CF Quality of Life questionnaire, ESS = Epworth sleepiness scale, PSQI = Global score Pittsburgh Sleep Quality Index, MRC =
Medical Research Council Dyspnoea Scale.
a p-value adjusted for FEV1, awake PaO2 and PaCO2.
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these parameters. No effect was seen on QoL at the ‘10%
threshold’ (SpO2b90% for≥10% of the recording time) or when
correlated against continuous measures of nocturnal SpO2. These
findings suggest that nocturnal oxyhaemoglobin desaturation at
the 30% threshold has an independent effect on QoL in CF.
Previous studies found a similar prevalence of nocturnal
oxyhaemoglobin desaturation in CF. CF subjects with an
FEV1b60% predicted spent 30% of the night with an
SpO2b90% [22]. Another study of 70 adult CF patients with
FEV1 20–100% predicted detected nocturnal oxyhaemoglobin
desaturation (defined as SpO2b90% for N5% of sleep time) in
40% of subjects [4]. However, the only randomised placebo-
controlled trial of long-term nocturnal oxygen therapy in CF
demonstrated no improvement in QoL, although there was
better maintenance of school and work attendance with
treatment [23]. Of note, patients in this trial had moderate not
severe daytime hypoxemia (PaO2b65 mm Hg), had no assess-
ment for nocturnal oxyhaemoglobin desaturation, received
oxygen therapy for a mean of seven hours per night and were
assessed with non-standardised questionnaires, all of which
could have contributed to the negative result.
This study utilised home overnight oximetry rather than
laboratory-based polysomnography as it was more convenient,
less invasive and therefore less likely to limit recruitment.
Arterial pulse oximetry can provide a reproducible measure of
nocturnal oxygenation in patients with CF [24]. A study of CF
patients with pulse oximetry in the hospital setting revealed
little night to night variability [11]. Similar consistency was
demonstrated using overnight oximetry in CF subjects at home
[10].
The choice of the 10% and 30% thresholds to define
nocturnal oxyhaemoglobin desaturation in this study were
based on national and international guidelines which recom-
mend implementing nocturnal oxygen therapy at varying levels
of hypoxia. The CF consensus conference guidelines recom-mend nocturnal oxygen therapy when the SpO2 is b88–90% for
≥10% of the night [12]. Australian guidelines for domiciliary
oxygen use in chronic lung disease, which determine local
funding approval, recommend nocturnal oxygen therapy when
the SpO2 is ≤88% for more than a third of the night [13].
However, it must be acknowledged that the definition of what
constitutes nocturnal oxyhaemoglobin desaturation will vary
from country to country and centre to centre due to the lack of
evidence supporting cutoffs for treatment and clinical signifi-
cance. Whether nocturnal oxyhaemoglobin desaturation carries
any clinical significance in CF patients at any level has been the
subject of controversy [25]. Given the limited trial data
supporting nocturnal oxygen therapy in CF, the current study
investigated whether a threshold for nocturnal oxyhaemoglobin
desaturation existed that was associated with clinical deterio-
ration. The findings indicated the 30% threshold, but not the
10% threshold, was associated with impaired QoL. However,
further research is clearly required to determine if nocturnal
oxygen therapy is beneficial in CF.
Mean and minimum nocturnal SpO2 levels have also been
used as a measure of nocturnal oxyhaemoglobin desaturation in
CF [5,26]. Therefore, data was also analysed in the current
study using continuous measures of nocturnal oxyhaemoglobin
desaturation. There was no observed effect of mean or
minimum nocturnal SpO2 on QoL. A possible explanation is
that the detrimental effects of nocturnal oxyhaemoglobin
desaturation may become apparent when the SpO2 falls below
90%. Alternatively, the skewing of these values towards the
upper end of the scale at 90 to 100% may make it difficult to
demonstrate an effect using linear correlations.
It is interesting to speculate on how nocturnal oxyhaemo-
globin desaturation might influence QoL in CF. In the current
study, nocturnal oxyhaemoglobin desaturation was associated
with greater difficulty in performing treatments, increased
exertional dyspnoea and trended towards a reduction in physical
functioning. Nocturnal oxyhaemoglobin desaturation has been
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function in CF [8,9], both of which could reduce treatment
adherence. Nocturnal oxyhaemoglobin desaturation has also
been linked to the presence of pulmonary hypertension in CF
[7], which could increase exertional dyspnoea and reduce
exercise capacity.
The strengths of this study included assessment of patients
during periods of clinical stability to limit the variability in
nocturnal oxyhaemoglobin desaturation which occurs during CF
exacerbations [9]. The sample size allowed for correction of the
main collinear confounding factors, namely lung function and
awake gas exchange. The use of CF-specific validated ques-
tionnaires, which have only recently become available, have added
to the legitimacy of the study findings. Analysis of nocturnal
oxyhaemoglobin desaturation at the 10% and 30% thresholds
determined a level at which clinical deterioration could occur.
There are several weaknesses of this study which need to be
considered. The design was cross-sectional and thus cannot be
used to provide evidence of causation. The study was
underpowered as 18 patients were required in both the non-
desaturator and desaturator groups. Thus, negative findings may
reflect false negatives due to the sample size. Correction for the
main confounding factors of lung function and awake gas
exchange were undertaken, but other factors may explain the
differences in QoL. In CF, there is often a collinear relationship
between disease variables that tend to worsen in parallel. A
larger sample size would be required to correct for all possible
confounding factors. Polysomnography was not used to record
differences in sleep architecture which could have contributed
to the observed effects. Measurement of pulmonary arterial
pressures and neurocognitive testing may have provided useful
information on the mechanisms linking nocturnal oxyhaemo-
globin desaturation to impaired QoL.
In conclusion, this study has demonstrated clinically signif-
icant nocturnal oxyhaemoglobin desaturation in 18% of stable CF
patients with moderate to severe lung disease using a cutoff of
SpO2b90% for ≥30% of the recording time on overnight
oximetry. Desaturators had impaired QoL compared to non-
desaturators after correcting for the effects of FEV1, awake PaO2
and PaCO2. An SpO2b90% for ≥30% of the recording time on
overnight oximetry appeared to be a clinically relevant threshold
for nocturnal oxyhaemoglobin desaturation, but trials of treatment
with nocturnal oxygen are required to confirm this assumption.
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